Literature DB >> 16840780

CD8alphabeta has two distinct binding modes of interaction with peptide-major histocompatibility complex class I.

Hsiu-Ching Chang1, Kemin Tan, Yen-Ming Hsu.   

Abstract

Interaction of CD8 (CD8alphaalpha or CD8alphabeta) with the peptide-major histocompatibility complex (MHC) class I (pMHCI) is critical for the development and function of cytolytic T cells. Although the crystal structure of CD8alphaalpha.pMHCI complex revealed that two symmetric CD8alpha subunits interact with pMHCI asymmetrically, with one subunit engaged in more extensive interaction than the other, the details of the interaction between the CD8alphabeta heterodimer and pMHCI remained unknown. The Ig-like domains of mouse CD8alphabeta and CD8alphaalpha are similar in the size, shape, and surface electrostatic potential of their pMHCI-binding regions, suggesting that their interactions with pMHCI could be very similar. Indeed, we found that the CD8alpha variants CD8alpha(R8A) and CD8alpha(E27A), which were functionally inactive as homodimers, could form an active co-receptor with wild-type (WT) CD8beta as a CD8alpha(R8A)beta or CD8alpha(E27A)beta heterodimer. We also identified CD8beta variants that could form active receptors with WT CD8alpha but not with CD8alpha(R8A). This observation is consistent with the notion that the CD8beta subunit may replace either CD8alpha subunit in CD8alphaalpha.pMHCI complex. In addition, we showed that both anti-CD8alpha and anti-CD8beta antibodies were unable to completely block the co-receptor activity of WT CD8alphabeta. We propose that CD8alphabeta binds to pMHCI in at least two distinguishable orientations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840780     DOI: 10.1074/jbc.M604931200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation.

Authors:  Ruth K Moysey; Yi Li; Samantha J Paston; Emma E Baston; Malkit S Sami; Brian J Cameron; Jessie Gavarret; Penio Todorov; Annelise Vuidepot; Steven M Dunn; Nicholas J Pumphrey; Katherine J Adams; Fang Yuan; Rebecca E Dennis; Deborah H Sutton; Andy D Johnson; Joanna E Brewer; Rebecca Ashfield; Nikolai M Lissin; Bent K Jakobsen
Journal:  Protein Cell       Date:  2011-01-08       Impact factor: 14.870

2.  Structural basis of the CD8 alpha beta/MHC class I interaction: focused recognition orients CD8 beta to a T cell proximal position.

Authors:  Rui Wang; Kannan Natarajan; David H Margulies
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

3.  The crystal structure of CD8 in complex with YTS156.7.7 Fab and interaction with other CD8 antibodies define the binding mode of CD8 alphabeta to MHC class I.

Authors:  D A Shore; H Issafras; E Landais; L Teyton; I A Wilson
Journal:  J Mol Biol       Date:  2008-10-07       Impact factor: 5.469

4.  Immunoglobulin-like transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming.

Authors:  Jacques Banchereau; Sandra Zurawski; LuAnn Thompson-Snipes; Jean-Philippe Blanck; Sandra Clayton; Adiel Munk; Yanying Cao; Zhiqing Wang; Sunaina Khandelwal; Jiancheng Hu; William H McCoy; Karolina A Palucka; Yoram Reiter; Daved H Fremont; Gerard Zurawski; Marco Colonna; Andrey S Shaw; Eynav Klechevsky
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

5.  Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control.

Authors:  Inez Johanna; Patricia Hernández-López; Sabine Heijhuurs; Wouter Scheper; Laura Bongiovanni; Alain de Bruin; Dennis X Beringer; Rimke Oostvogels; Trudy Straetemans; Zsolt Sebestyen; Jürgen Kuball
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

6.  Human Peripheral Blood Gamma Delta T Cells: Report on a Series of Healthy Caucasian Portuguese Adults and Comprehensive Review of the Literature.

Authors:  Sónia Fonseca; Vanessa Pereira; Catarina Lau; Maria Dos Anjos Teixeira; Marika Bini-Antunes; Margarida Lima
Journal:  Cells       Date:  2020-03-16       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.